The efficacy, electrophysiologic effects, and side effects of adenosine triphosphate (ATP) and verapamil in the short-term management of paroxysmal reciprocating junctional tachycardia (PRJT) were compared in 20 patients. All patients had inducible sustained PRJT during control electrophysiologic study. Fourteen patients had PRJT involving a retrograde accessory pathway, and six patients had atrioventricular (AV) nodal reentrant tachycardia ("slow-fast" type). ATP, which has a very short half-life, was first administered (10 mg iv over 1 sec) during sustained PRJT. If PRJT did not terminate within 2 min, a bolus of 20 mg ATP was given. Verapamil (5 mg iv over 15 sec) was subsequently administered during sustained PRJT, and if the latter did not terminate within 3 min another bolus of 5 mg verapamil was given. The cycle lengths of PRJT before administration of 10 or 20 mg ATP and 5 mgverapamil were similar. The 10 mg dose of ATP terminated PRJT in 17 of the 20 patients, and 20 mg ATP was required to terminate PRJT in the three remaining patients. The 5 mg dose of verapamil terminated PRJT in 15 patients, whereas an additional bolus of 5 mg terminated PRJT in one of the remaining five patients. The overall efficacy of ATP (20/20, 100%) was significantly greater than that of verapamil (16/20, 80%) (p < .05); however, there was no significant difference between the conversion rate of PRJT after administration of 10 mg ATP (17/20) and 5 mg verapamil (15/20). ATP terminated PRJT more quickly than verapamil (mean 24 sec vs mean 51 sec; p < .01). Termination of PRJT by either ATP or verapamil was mainly related to a block in the AV node in patients with accessory pathways and to a block in the antegrade slow pathway in patients with AV nodal reentry. Cycle length alternans before termination of tachycardia was observed more frequently after verapamil than after ATP (7/16 vs 1/20; p < .01). The total incidence of transient second-degree AV nodal block and various cardiac supraventricular and ventricular arrhythmias was higher after termination of PRJT by ATP than after verapamil (17/20 vs 5/16; p < .001). A higher incidence of transient but frequently uncomfortable noncardiac side effects was observed after ATP. We conclude that ATP (10 to 20 mg) is more effective and more rapid than verapamil (5 or 5 + 5 mg) in terminating PRJT but results in a higher incidence of cardiac and noncardiac side effects. We therefore recommend its use only if a cumulative dose of 10 mg verapamil has failed to terminate PRJT, if verapamil is contraindicated, or if a very rapid conversion to sinus rhythm is deemed urgent. knowledge, the effects of ATP and verapamil on paroxysmal supraventricular tachycardia were compared in only one previous study.3 In this study, however, the drugs were administered to different groups of patients and no electrophysiologic data were provided.
cular tachycardia, (2) inducible sustained PRJT during electrophysiologic study (durations more than 10 min), (3) good hemodynamic tolerance of the tachycardia, and (4) no contraindication to the administration of verapamil (congestive heart failure, marked hypotension) and ATP (asthma).7 ' 8 The study group included 20 patients (13 men, seven women) with a mean age ( + SD) of 36 + 17 years. None of the patients studied had evidence of organic heart disease. Clinical characteristics of these patients are listed in table 1. Electrophysiologic studies. Electrophysiologic studies were performed with the patient in the fasting, nonsedated state after informed written consent had been obtained. All drugs, including those known to interfere with adenosine metabolism (e.g., aminophylline, dipyridamole, and diazepam), were discontinued for at least five half-lives before the study. No patient had received amiodarone during the 3 months before the study. One bipolar and two quadripolar electrode catheters (USCI, No. 6F) were introduced through the right femoral vein and placed at the high right atrium, right ventricular apex, and AV junction (for His bundle recording). The distal pair of the quadripolar electrodes was used for pacing and the proximal pair for recording intracardiac activity. When the atrial activity during induced PRJT was not synchronous with the QRS complex (i.e., in all patients with retrogradely conducting accessory pathways), left atrial activity was recorded by an additional quadripolar electrode catheter positioned in the coronary sinus (eight patients), the pulmonary artery trunk (four patients), or the left atrium via a patent foramen ovale (two patients). Standard electrocardiographic leads I, II, III, and V1, as well as the intracardiac electrograms, were simultaneously recorded on an eight-channel recorder (Mingograph Elema 82). Stimuli of 2 msec in duration and 3 mA intensitywere delivered by a programmable stimulator (Medtronic Model 5325). Tracings were recorded at a paper speed of 100 mm/sec. Accuracy of measurements was + 5 msec.
Protocol of stimulation. The protocol for atrial and ventricular stimulation was as follows: (1) atrial extrastimulation during atrial pacing at several cycle lengths, (2) incremental atrial pacing up to a cycle length of 250 msec or until seconddegree AV block was obtained, (3) ventricular extrastimulation during ventricular pacing at several cycle lengths as well as during induced tachycardia, and (4) incremental ventricular pacing up to a cycle length of 300 msec or until second-degree ventriculoatrial (VA) block was obtained.
Definitions. Arrhythmia mechanisms were determined on the basis of retrograde atrial activation patterns and responses to cardiac stimulation. AV nodal reentry was diagnosed by a combination of the following criteria: (1) induction of tachycardia related to achievement of a critical AV nodal (AH) delay, (2) demonstration of "discontinuous" A1A2, H1H2 curves with induction of tachycardia related to antegrade block in the fast pathway, (3) retrograde atrial activation synchronous with the QRS complex of the tachycardia, (4) activation of the low right atrium during tachycardia and ventricular pacing before other atrial sites, and (5) inability to preexcite the atrium during PRJT by a premature ventricular stimulus when the His bundle was refractory. The involvement of an accessory pathway conducting retrogradely was diagnosed when the following were observed during PRJT: (1) eccentric retrograde activation sequence, (2) increase in VA conduction time when bundle branch block occurred ipsilateral to the accessory pathway, and (3) preexci- AH = interval from the earliest atrial deflection to the His bundle activity in the His bundle lead; APCLW = atrial paced cycle length that resulted in second-degree antegrade AV nodal block; AVNR = atrioventricular nodal reentry; AVR = atrioventricular reentry; (C) = concealed accessory pathway; HV = interval from the onset of His bundle activity to the earliest deflection of the QRS complex; NA = not available (refractory period of the AV node longer than that of the accessory pathway); NI = normal; RBBB = right bundle branch block; SRCL = sinus rhythm cycle length; WPW = Wolff-Parkinson-White syndrome.
THERAPY AND PREVENTION-ARRHYTHMIA tation of the atria by a premature ventricular stimulus when the If tachycardia did not terminate within 2 min, a dose of 20 mg His bundle was refractory. Since the earliest area of retrograde ATP was then administered. Since PRJT was always termiatrial activation during PRJT is frequently difficult to determine nated by either 10 or 20 mg ATP, higher doses were not given. accurately in patients with AV nodal reentry and in those with After a resting period of 5 min during which the patient was septal accessory pathways, we elected to determine the retro-in sinus rhythm, PRJT was reinduced with cardiac stimulation. grade atrial activity from the high right atrial electrogram in all After the tachycardia was allowed to continue for 5 min, a dose patients. of 5 mg verapamil was administered. If tachycardia did not Drug administration. Verapamil (Ikacor; Teva Lab., Israel) terminate within the 3 min after completion of this injection, and ATP (Striadyne; Lab. Auclair, France) were administered an additional dose of 5 mg verapamil was given over a 15 sec intravenously into a femoral vein. Verapamil was injected within period. a 15 sec period as recommended when a prompt drug response Data analysis. The interval between drug administration and is desired2; ATP was injected very quickly, in less than 1 sec, end of tachycardia, the effects of drugs on the cycle length, the since a slow injection rate is known to be a definite cause of drug mode of termination of tachycardia, the pause at termination, failure.
and side effects were noted in all patients. Data were statistically During control electrophysiologic study, the characteristics of analyzed by Student's t test for paired data as well as the antegrade and retrograde AV conduction were assessed along chi-square test. A p value < .05 was regarded as significant. All with the modes of induction and termination of PRJT and the data are expressed as mean + SD. effects of premature ventricular stimulation during tachycardia. During this evaluation, PRJT did not terminate spontaneously Results and was sustained for at least 10 min in all patients. After Electrophysiologic control data (table 1). In 14 patients completion of the control electrophysiologic study, sinus rhythm electrphsiologic c ntolvdata (tabl e aties was restored for a few minutes. PRJT was subsequently rein-the mechanism of PRJT involved a retrograde accesduced with programmed cardiac stimulation and was allowed to sory pathway. Nine patients had Wolff-Parkinsoncontinue for 5 min without any intervention. In all patients the White syndrome and five had a concealed accessory tachycardia did not spontaneously terminate and spontaneous atrial or ventricular arrhythmias were not observed during this pathway (normal resting electrocardiogram in four and period. An initial dose of 10 mg ATP was then administered.
right bundle branch block in one). In six patients the 25 A'H = time from the earliest high-frequency deflection of the high right atrial electrogram during tachycardia to the His bundle activity; CL = cycle length of the tachycardia; VA' = time from the earliest deflection of the QRS during tachycardia to the earliest deflection of the high right atrial electrogram. VPC = ventricular premature complexes. AFollowed by retrograde atrial activity. BNot followed by retrograde atrial activity. (2) APC (1) VPCs (4), PRJT (T 16 sec)
VPCs (3), APCs (2) VPCs (16) AF(T2 sec-T 74 sec) VPCs(2), APCs(2), HPCs(2) VPC(1), APCs (7) , AF(T 100 sec-T 2 hr) VPC(1), Atrial couplets (2) VPC (1) APCs (5) VPCs (17), AF(T 30 sec-T 4 hr) Nonsustained PRJT (3) APCs (3), PRJT(T 17 sec)
A'A = interval from the last retrograde atrial activity during tachycardia to the first posttachycardia atrial complex; AA max = maximal interval between two sinus beats within the 30 sec after termination of tachycardia; AF = atrial fibrillation; APCs = atrial premature complexes; HPCs = His premature complexes; NA = not available (presence of VPCs preventing accurate measurements or lack of termination of the tachycardia after drug administration); NSVT = nonsustained ventricular tachycardia; VPCs = ventricular premature complexes; Ver = verapamil.
ASecond-degree AV block after tachycardia termination. BThe number in parentheses represents either the number of complexes in the arrhythmia or the interval (T) to onset of the arrhythmias after tachycardia termination. mechanism of PRJT was AV nodal reentry of the "slow- Tracings from upper and lower panel are continuous. Twenty-one seconds after administration of 10 mg ATP, PRJT terminates due to block in the antegrade slow nodal pathway after progressive prolongation of the A'H interval. Two seconds after conversion to sinus rhythm, atrial fibrillation occurs. Note two wide QRS complexes during atrial fibrillation that probably have a ventricular origin, although a supraventricular origin with aberration is not ruled out.
In all 20 patients, the cycle lengths of PRJT before administration of 10 mg ATP and 5 mg verapamil were similar (317 + 54 vs 322 + 50 msec; p = NS). In the three patients who received 20 mg ATP, the cycle lengths of PRJT were similar before 20 mg ATP and 5 mg verapamil. AV HRA A --FIGURE 2. Termination of PRJT by ATP but not verapamil in a patient with AV nodal reentry (patient 5). Shown are electrocardiographic lead V1 and intracardiac electrograms from the atrioventricular junction (AV) and high right atrium (HRA). ATP (10 mg) terminates PRJT 25 sec after administration due to block in the slow antegrade AV nodal pathway after cycle length alternans (A'H alternans). In contrast, PRJT is slowed but not terminated by 5 
. Ventricular excitability after ATP but not verapamil in a patient with a left posteroseptal accessory pathway (patient 1). Shown are electrocardiographic leads I, II, III, and V1 and intracardiac electrograms from the distal coronary sinus (DCS), proximal coronary sinus (PCS), atrioventricular junction (AV), and high right atrium (HRA).
PRJT is terminated 18 sec after administration of 10 mg ATP due to AV nodal block. Immediately after conversion, nonsustained irregular ventricular tachycardia (7 beats) with 1: 1 retrograde conduction through the accessory pathway is observed. In contrast, 5 mg verapamil (VER) terminates PRJT 30 sec after administration due to AV nodal block after cycle length alternans but with no ventricular arrhythmia. grade conduction through the AV node after a progressive prolongation of A'H interval (15 patients) and A'H alternans (one patient) (figures 1 and 2). In four patients (Nos. 7, 11, 12, and 14) ventricular premature complexes occurred at the time of tachycardia termination. In two of these patients (Nos. 11 and 14) no prolongation of A'H interval was seen before termination. No change in HV or VA' intervals was observed in any of the 20 patients after ATP administration.
The interval from the last retrograde atrial activity during PRJT to the first posttachycardia sinoatrial complex ranged from 620 to 1050 msec (mean 841 ± 140 msec, n = 15) after the dose of ATP that terminated the tachycardia. The longest sinus rhythm cycle length after tachycardia termination by ATP ranged from 550 to 1320 msec (mean 926 ± 225 msec, n = 20). After termination of tachycardia, transient (5 to 6 sec) second-degree AV nodal block was observed in four patients (Nos. 5, 8, 18, and 20) . Atrial, His, and/or ventricular premature complexes were noted in nine patients within the first minute after termination of tachycardia. Nonsustained ventricular tachycardia (7 beats) or PRJT (3 beats) were observed in one patient each (Nos. 1 and 19, respectively) ( figure 3 ). Sustained PRJT triggered by an atrial or ventricular premature 800 complex occurred in two patients 16 to 17 sec after termination of tachycardia (patients 10 and 20, respectively). Atrial fibrillation developed 2 sec after termination of tachycardia in one patient (No. 13) and spontaneously ended 72 sec later (figure 1). In this patient atrial fibrillation was not documented before electrophysiologic study nor during programmed atrial stimulation before administration of ATP. In all patients the arrhythmias observed were well tolerated and did not require specific intervention except in patients 10 and 20. whose sustained PRJT required cardiac pacing for termination. Efects of verapamil (tables 3 and 4). The 5 mg dose of verapamil terminated PRJT in 15 patients. In the five remaining patients an additional bolus of 5 mg verapamil was given but terminated PRJT in only one instance. Prolongation of A'H interval without change in HV interval was noted in all patients after verapamil. VA' interval remained unchanged in all patients except one who showed slight prolongation (patient 14). Termination of PRJT occurred 30 to 160 sec (mean 51 + 32 sec) after completion of the effective dose of verapamil. This termination was related to an antegrade block in the AV node (A'H) in 14 patients (figure 3) and to a retrograde AV nodal block in one patient (No. 14). In one patient (No. 13), a premature ventricular complex occurred at the time of tachycardia termination. Cycle length alternans was observed before termination of tachycardia in seven of the 16 patients (Nos. 2, 10 to 12, 16, 18, and 19) ( figure 3 ). Of the 16 patients in whom verapamil terminated the tachycardias, the last QRS complex before termination of tachycardia was identical to that of the tachycardia in all patients but one. In the latter patient (No. 18), the left bundle branch block present during tachycardia disappeared on the last complex before termination of tachycardia.
The interval from the last retrograde atrial activity during PRJT to the first posttachycardia sinoatrial complex ranged from 565 to 1080 msec (mean 802 + 152 msec, n = 15). The longest sinus rhythm cycle length after termination of tachycardia by verapamil ranged from 500 to 950 msec (mean 685 + 130 msec, n = 16). Second-degree AV block was not observed in any patient after termination of tachycardia with verapamil. Atrial and/or ventricular premature complexes were observed in three patients within the first minute after termination of tachycardia. Sustained atrial fibrillation developed in two patients (Nos. 14 and 18) 100 and 30 sec, respectively, after termination of tachycardia. The arrhythmia was well tolerated and spontaneously converted to sinus rhythm without any specific treatment within a few hours. In both patients, AMeasured from completion of verapamil infusion to termination of tachycardia.
BNot followed by retrograde atrial activity.
atrial fibrillation was not documented before elecwas facial flushing (15 patients). Headaches and dysptrophysiologic study nor during programmed atrial nea occurred in five and nine patients, respectively. stimulation before administration of verapamil.
Cough was observed in two patients and both chest pain Comparative efficacy and electrophysiologic effects of and nausea in another patient. In the three patients who ATP and verapamil. The comparative efficacy of ATP were given both 10 mg and 20 mg ATP, identical side and verapamil in converting PRJT is summarized in effects were noted with both doses. No side effects were table 5. The overall efficacy of ATP (10 or 20 mg) was noted after verapamil. significantly higher than that of verapamil (5 or 5 + 5 mg) (20/20 vs 16/20; p < .05). However, there was no Discussion significant difference between the conversion rate of Study design. In our study, the cycle lengths of the PRJT after 10 mg ATP and 5 mg verapamil (17/20 vs induced PRJT were similar before administration of 15/20; p = NS). Conversion of tachycardia occurred ATP and the first dose of verapamil, allowing commore quickly after ATP than after verapamil (mean 24 parison of the effects of these agents during a single ± 8 vs mean 51 + 32 msec; p < .01). The most electrophysiologic study. This finding was due to the pertinent electrophysiologic effects of ATP and veravery short half-life of ATP, which was tested before pamil are compared in table 6. verapamil. ATP is almost entirely metabolized to ade-Side effects of ATP and verapamil. Clinical side effects nosine during a single passage through the heart.5 ' 6 In were frequently noted after administration of ATP but man, the effects of ATP are believed to depend mainly they were short lasting (less than 1 min) and did not on its conversion to adenosine,10 11 which has a require any treatment. The most common side effect half-life of less than 10 sec,'2 being quickly degraded to the electrophysiologically inactive inosine. This short half-life is responsible for the very transient duration of the effects of ATP and the return to control electrophysiologic values within 2 min after its administration. 13
Efficacy of ATP. In the present study, a dose of 10 or 20 mg ATP terminated PRJT in all 20 patients (100% efficacy rate). These findings are consistent with the results of previous studies in adult patients showing termination of PRJT in 94% to 98% of cases after administration of 20 mg ATP9"14 and in 98% to 100% of cases after a dose of 10 to 20 mg. 15' 16 However, in the two latter reports, the effects of the administration of 10 mg ATP alone either were not indicated15 or were evaluated in only a few patients.16 In this regard, our data showed that a dose of 10 mg ATP was successful in 85% (17/20) of our patients and that a dose of 20 mg ATP was required to terminate PRJT in only 15% of cases. Since the electrophysiologic effects of ATP, especially the depression of AV nodal conduction, are dose related,17 our results suggest that a dose of 10 mg ATP should be tried first for treating PRJT and that a higher dose (15 or 20 mg) should be used only when this initial dose fails.
Efficacy of verapamil. Our data showed that a dose of 5 mg verapamil terminated PRJT in 15 patients, whereas an additional dose of 5 mg was required to abolish tachycardia in another patient (overall efficacy rate of 80%). These results compare favorably with the 63% to 100% (mean 87%) conversion rate previously reported after administration of 3.5 to 10 mg verapamil in adult patients. [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] The fact that a dose of 5 mg verapamil was successful in 15 of the 16 patients who responded to verapamil suggests that a dose of 5 mg verapamil and not a dose of 10 mg should be tried first in the short-term management of PRJT. Such a protocol might minimize the risk of deleterious hemodynamic effects sometimes observed with this negative inotropic agent. 802 Comparative efficacy ofATP and verapamil. The effects of ATP and verapamil on the termination of paroxysmal supraventricular tachycardia have been previously compared in only one report.3 In that study, performed in infants and children, Greco et al. found that ATP was as effective as verapamil in terminating the tachycardia (both 90% success rate). However, the efficacy of the drugs was not compared in the same patients. In the present study, we compared the efficacy of ATP and verapamil on PRJT in the same patients. We found that the overall efficacy rate of ATP (10 or 20 mg) was significantly greater than that of verapamil (5 or 5 + 5 mg) but that there was no significant difference between the efficacy of 10 mg ATP and 5 mg verapamil. In addition, we found that termination of PRJT occurred more quickly after ATP than after verapamil.
Since the electrophysiologic effects of ATP in man are believed to be mainly due to its conversion to adenosine,10 11 Thus both ATP and adenosine appear to be more effective than verapamil in terminating paroxysmal supraventricular tachycardia. However, it is difficult to compare the doses of ATP and adenosine required to terminate tachycardia in Sellers' study and ours for two reasons: (1) graded doses of adenosine were used by Sellers et al., whereas fixed doses of ATP were used in our study, and (2) the molecular weight of ATP is about twice that of adenosine (551 vs 267). Therefore further studies with equimolar doses of ATP and adenosine are required to compare the actual potency of these agents on PRJT.
Comparative electrophysiologic effects of ATP and verapamil. Consistent with previous reports, 9' 20, 23-25, 27 both drugs terminated most episodes of PRJT after block in the slow antegrade AV nodal pathway (in patients with AV nodal reentry) or in the AV node (in patients with retrograde accessory pathways). Ventricular premature complexes were noted at the time of tachycardia termination in four patients after ATP and in one patient after verapamil and were probably responsible for this termination. Such a modality of tachycardia termination has been previously well documented for verapamil27' 29 but not for ATP9' 16 or adenosine.30 Interestingly, two patients who exhibited this phenomenon after administration of ATP did not show any change in A'H interval, suggesting that the occurrence of ventricular arrhythmias was critical for termination of tachycardia in these patients. Several differences were observed between the electrophysiologic effects of ATP and verapamil: (1) cycle length alternans before termination of tachycardia occurred more frequently in patients who responded to verapamil than in those who responded to ATP (7/16 vs 1/20). Although the phenomenon of cycle length alternans after administration of verapamil is well known 23-25, 27, 31 its rarity after administration of ATP suggests different electrophysiologic effects of ATP and verapamil on the AV node. (2) A second difference between the two drugs was that the longest sinus cycle length after termination of tachycardia was greater after ATP, suggesting that this agent exerts more potent depressant effects on sinus node automa-Vol. 77, No. 4, April 1988 ticity than verapamil. (3) A third difference between the two drugs relates to the incidence of AV nodal conduction and various supraventricular and ventricular arrhythmias observed after termination of PRJT. Although none of these disturbances taken alone occurred more significantly with either drug, their overall incidence was significantly greater after ATP than after verapamil (17/20 vs 5/16). However, in most cases these disturbances were transient and well tolerated and did not require any specific treatment.
An interesting finding of our study was the occurrence of sustained atrial fibrillation in two patients after verapamil and of short-lasting atrial fibrillation in one patient after ATP. Induction of atrial tachyarrhythmias has been reported occasionally after conversion of PRJT with verapamil,21 ATP,32 or adenosine.30 In patients without Wolff-Parkinson-White syndrome, as in the three patients in our study, such arrhythmias have no deleterious outcome. However, they may result in life-threatening arrhythmias in patients with preexcitation syndromes associated with a short refractory period of the accessory pathway. Although we are not aware that any such deleterious effect has been reported in the literature, our data suggest that one should be careful when administering either ATP or verapamil to patients with PRJT and preexcitation syndromes. Particular attention should be given when administering verapamil, since a recent study has shown an increased inducibility and persistence of atrial fibrillation in patients who were given this drug.33 Clinical side efrects. ATP resulted in a high incidence of side effects. Although these were minor, transient, and had a benign outcome, they were uncomfortable for many patients. In contrast, verapamil was well tolerated in all cases. However, we did not include in the present study patients with hemodynamically poorly tolerated tachycardias or with congestive heart failure, or those pretreated with 3-blocking agents, all ofwhom have been shown to be the most prone to develop severe complications after administration of verapamil. Because of its very short half-life, ATP should be preferred to verapamil in such patients.
Limitations of study. A limitation of the present study is that we used a commercially available preparation of ATP (Striadyne), which has been shown by high-performance liquid chromatography analysis to contain mostly ATP but also adenosine and other nucleotides. 32 However, although there are no data comparing Striadyne and ATP in man, both agents have been found to have similar electrophysiologic effects in the canine heart,17' 34 suggesting that the residual contamination of Striadyne with adenine compounds does not modify its effect as compared with that of ATP alone. Another possible limitation of our study is that we administered verapamil more slowly (over 15 sec) than ATP (over 1 sec), and therefore it may be argued that a faster administration rate of verapamil might have resulted in higher initial plasma drug concentrations and thus in a higher success rate of conversion of PRJT. However, it should be noted that the rate of administration ofverapamil in our study was consistent with that recommended in clinical practice when a prompt response is desired2; in addition, in most previous reports verapamil was administered more slowly than in the present study: over 15 to 30 sec in one report20 and over 30 sec to 4 min in the others. [21] [22] [23] [24] [25] [26] [27] Finally, the assessment of cardiac arrhythmias after conversion of tachycardias may have been limited by the presence of multiple catheters in the heart. However, we believe that such a limitation, which is inherent to any electrophysiologic study, is of minimal importance in the present study, based on the following: (1) none of our patients had spontaneous atrial or ventricular arrhythmias during induced PRJT before drug administration, (2) the postconversion arrhythmias always occurred at the time of the expected maximal effect of the drugs, and (3) postconversion atrial and ventricular arrhythmias similar to those noted in our study were previously observed in several reports in which either ATP or verapamil was administered in patients who did not undergo invasive electrophysiologic studies. 14, 20, 29 Clinical implications. The results of this study show that intravenous administration of 10 to 20 mg ATP is more effective and more rapid than that of 5 or 5 + 5 mg verapamil in terminating PRJT. Therefore ATP may be a drug of first choice in the short-term management of this arrhythmia, especially when very rapid conversion to sinus rhythm is deemed to be urgent because of clinical considerations. In addition, "low" doses of ATP and verapamil (10 mg and 5 mg, respectively) have similar efficacy rates and are sufficient to terminate most cases of PRJT. However, ATP results in a higher incidence of AV conduction disturbances and cardiac arrhythmias than verapamil. Although the former are transient and well tolerated, the latter may provoke reinitiation of PRJT that may require administration of another dose of ATP because of the very short half-life of the drug. In contrast, the longer halflife ofverapamil would make reinitiation of PRJT more difficult should premature complexes occur after drug administration. In addition, ATP results in a higher incidence of noncardiac side effects that are frequently uncomfortable for the patients in contrast to the excel-804 lent tolerance of verapamil. Based on these findings, we recommend the use of verapamil and not of ATP as the first drug for terminating PRJT. We believe that ATP should be given only to the following groups of patients with PRJT: (1) those who do not respond to a cumulative dose of 10mg verapamil, (2) those in whom verapamil is contraindicated (hypotension, congestive heart failure, left ventricular dysfunction, pretreatment with ,B-blocking agents), and (3) those in whom very rapid conversion to sinus rhythm is needed. In patients with PRJT and known sinus or AV nodal dysfunction, we also recommend the careful use of ATP because of its very short half-life. Using such a policy, we have been able to terminate safely all cases of PRJT observed in our institution during the last decade without resorting to additional antiarrhythmic agents, cardioversion, or cardiac pacing.
